|Bid||179.51 x 800|
|Ask||179.80 x 900|
|Day's Range||179.66 - 179.77|
|52 Week Range||111.75 - 189.99|
|Beta (5Y Monthly)||0.35|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||154.50|
The purchase of Acceleron Pharma gives Merck one more arrow in its quiver as it prepares for the patent on its blockbuster cancer therapeutic Keytruda to expire.
The list, released Wednesday, ranks the fastest-growing technology, media, telecommunications and life sciences companies based in North America.
Avoro Capital, holder of a 7% Acceleron stake, urged fellow investors not to tender their shares to Merck. Avoro doesn’t like the price or the timing.